Ad tiers and price hikes drive revenues, but churn and subscription fatigue challenge platforms and marketers.
The field is new, the terminology is unsettled, and vendor hype runs high. This FAQ separates what's real from what's speculative.
Patients mostly want AI use to supplement professional advice, but stigma prevents them from admitting it. Providers and marketers can guide smarter, transparent AI use.
As automation takes over buying, curated deals cut waste, and clean rooms merge data without exposing users
$57 billion will flow to automated ads as marketers trade visibility for speed and returns
AI is moving upstream, showing up earlier in the decision-making process and increasingly shaping what happens next.
Newsom mandates safety disclosures, bias checks, and watermarking, defying Washington’s lighter-touch stance.
Instagram’s upgraded model boosts ROAS with less compute, nudging marketers toward hands-off buying.
Low-cost clicks give marketers insight into Amazon’s rankings, but thin volume and opaque chats curb impact.
Usage is common but confidence lags and job concerns persist, forcing brands to prove value and transparency.
Calls grow to restrict AI-generated content, prompting marketers to reassess youth-focused placements.
As Apple celebrates its 50th anniversary, we dive into how the company has grown as leader in marketing, retail, and Services—and what’s next.
MPA backlash forces a rethink of borrowed ratings, exposing risks of using third-party trust markers.
A leaked Amazon deck positions its Rufus AI shopping assistant as a high-intent retail media channel with CPC pricing on the horizon.
Brand storytelling, iconic retail, and fast-rising Services lock in users and challenge rivals on profitability and loyalty.
New terms shift liability to customers as Gemini integration nears.
TotalView merges linear and CTV data across 70 million EU TVs, giving planners deduplicated, cross-channel clarity.
Slackbot unifies 8,600+ tools and agents, turning chat into a command center for enterprise workflows.
Its exclusive Insilico licensing reflects pharma’s move to AI-driven early discovery to speed development and trim costs.